BCAL DIAGNOSTICS OPENS NEW LABORATORY IN SYDNEY AS IT ACCELERATES DEVELOPMENT OF ITS BREAST CANCER BLOOD SCREENING TOOL
Retrieved on:
Thursday, May 4, 2023
SYDNEY, May 4, 2023 /PRNewswire/ -- BCAL Diagnostics Limited (ASX:BDX) (BCAL or Company) an Australian-based biotechnology company announced the opening of its development and clinical service laboratory in Sydney. This step marks an important milestone for the company as it advances commercialization of its non-invasive blood screening that is initially intended to be used alongside other breast cancer screening methods, with results to date demonstrating 91% sensitivity and 80% specificity. The technology will initially complement current imaging technologies, such as the mammogram, while BCAL further progresses the development of a monitoring and screening test suitable for women of all ages and backgrounds in any location.
Key Points:
- SYDNEY, May 4, 2023 /PRNewswire/ -- BCAL Diagnostics Limited (ASX:BDX) (BCAL or Company) an Australian-based biotechnology company announced the opening of its development and clinical service laboratory in Sydney.
- Patient samples will be collected and forwarded to BCAL's laboratory, where they will be tested for the proprietary BCAL lipid signature that is expressed by breast cancer cells.
- "We plan to use this laboratory for a variety of purposes leading up to and following product approval and availability.
- To learn more about BCAL Diagnostics or to participate in BCAL's research, you can register your interest online at www.bcaldiagnostics.com .